Voyager Therapeutics Inc - ESG Rating & Company Profile powered by AI
If you are employed by Voyager Therapeutics Inc and you wish to licence your Sustainability aseessment, please contact us. The report of Voyager Therapeutics Inc leverages data points from across the web and also from available disclosures by Voyager Therapeutics Inc. Check the bottom of the page for potential risks for Voyager Therapeutics Inc based on industry, location and marketcap.
Voyager Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.8; made up of an environmental score of 5.3, social score of 3.2 and governance score of 6.0.
4.8
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
764 | Zoetis Inc | 4.9 | High |
764 | iCo Therapeutics Inc | 4.9 | High |
816 | Voyager Therapeutics Inc | 4.8 | High |
816 | Chemomab Therapeutics Ltd | 4.8 | High |
816 | Althea Group Holdings Ltd | 4.8 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Voyager Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Voyager Therapeutics Inc disclose current and historical energy intensity?
Does Voyager Therapeutics Inc report the average age of the workforce?
Does Voyager Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Voyager Therapeutics Inc disclose its ethnicity pay gap?
Does Voyager Therapeutics Inc disclose cybersecurity risks?
Does Voyager Therapeutics Inc offer flexible work?
Does Voyager Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Voyager Therapeutics Inc disclose the number of employees in R&D functions?
Does Voyager Therapeutics Inc conduct supply chain audits?
Does Voyager Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Voyager Therapeutics Inc conduct 360 degree staff reviews?
Does Voyager Therapeutics Inc disclose the individual responsible for D&I?
Does Voyager Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Voyager Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Voyager Therapeutics Inc disclose water use targets?
Does Voyager Therapeutics Inc have careers partnerships with academic institutions?
Did Voyager Therapeutics Inc have a product recall in the last two years?
Does Voyager Therapeutics Inc disclose incidents of discrimination?
Does Voyager Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Voyager Therapeutics Inc issued a profit warning in the past 24 months?
Does Voyager Therapeutics Inc disclose parental leave metrics?
Does Voyager Therapeutics Inc disclose climate scenario or pathway analysis?
Does Voyager Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Voyager Therapeutics Inc disclose the pay ratio of women to men?
Does Voyager Therapeutics Inc support suppliers with sustainability related research and development?
Does Voyager Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Voyager Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Voyager Therapeutics Inc involved in embryonic stem cell research?
Does Voyager Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Voyager Therapeutics Inc disclose its waste policy?
Does Voyager Therapeutics Inc report according to TCFD requirements?
Does Voyager Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Voyager Therapeutics Inc disclose energy use targets?
Does Voyager Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Voyager Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Voyager Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.